English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12190/12972 (94%)
Visitors : 1091087      Online Users : 449
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version

    Category

    Loading community tree, please wait....

    Year

    Loading year class tree, please wait....

    Items for Author "Okusaka, T" 

    Return to Browse by Author

    Showing 8 items.

    Collection Date Title Relation Bitstream
    [陳立宗] 期刊論文 2023-07 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462 -
    [陳立宗] 會議論文/會議摘要 2022-11 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) -
    [陳立宗] 會議論文/會議摘要 2022-09 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) -
    [陳立宗] 期刊論文 2023-11 Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer -
    [陳立宗] 期刊論文 2024-08 Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study -
    [陳立宗] 期刊論文 2017-08 A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo -
    [陳立宗] 會議論文/會議摘要 2019-10 A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1 -
    [陳立宗] 會議論文/會議摘要 2022-02-01 A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1 -

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback